Search

Your search keyword '"Ganuza M"' showing total 3 results
Start Over Author "Ganuza M" Topic skin neoplasms
3 results on '"Ganuza M"'

1. Merkel Cell Carcinoma: A Description of 11 Cases.

Author

García-Zamora E, Vela Ganuza M, Martín-Alcalde J, Miñano Medrano R, Pinedo Moraleda F, and López-Estebaranz JL

Subjects
Aged, Female, Humans, Lymph Nodes, Male, Retrospective Studies, Spain, Carcinoma, Merkel Cell epidemiology, Skin Neoplasms epidemiology
Abstract

Merkel cell carcinoma (MCC) is a malignant neuroendocrine tumor. Metastasis or lymph node spread is often detected at diagnosis. We performed a descriptive, retrospective study of patients diagnosed with MMC at Hospital Universitario Fundación Alcorcón in the Community of Madrid, Spain between January 1998 and December 2018. Eleven patients (7 men [63%] and 4 women [36%]; mean age, 77.6 years) were diagnosed with MCC during this 21-year period; 45% of patients had stage IIIB disease (pTNM) at diagnosis. All patients but one underwent local surgery, and lymphovascular invasion was detected in 7 cases. Eight patients received adjuvant therapy after surgery (radiation therapy in 5 cases and chemotherapy in 3). Six patients (54%) died of MCC (mean survival, 14.5 months). MCC is an uncommon malignant tumor with an annual incidence of around 0.18 to 0.41 cases per 100 000 inhabitants; this is similar to the rate of 0.29 to 0.32 cases per 100 000 inhabitants a year detected in our series. Results with avelumab, a drug recently approved for the treatment of metastatic MCC; have been promising., (Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)

Published
2021
Full Text
View/download PDF

2. Kaposi sarcoma in an immunosuppressed young woman.

Author

García-Zamora E, Elosua-González M, Vela-Ganuza M, and López-Estebaranz JL

Subjects
Adult, Female, HIV Infections complications, Humans, Immunocompromised Host, Sarcoma, Kaposi complications, Skin Neoplasms complications, Sarcoma, Kaposi pathology, Skin Neoplasms pathology
Published
2018
Full Text
View/download PDF

3. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.

Author

Elosua-Gonzalez M, Lopez-Estebaranz JL, Garcia-Zamora E, Vela-Ganuza M, and Rodrigez-Vasquez X

Subjects
Acneiform Eruptions drug therapy, Adult, Dermatologic Agents therapeutic use, Drug Eruptions drug therapy, Female, Humans, Isotretinoin therapeutic use, Severity of Illness Index, Acneiform Eruptions chemically induced, Antineoplastic Agents adverse effects, Drug Eruptions etiology, Melanoma drug therapy, Skin Neoplasms drug therapy, Vemurafenib adverse effects
Abstract

Vemurafenib, a kinase inhibitor that targets tumors with the BRAF V600E mutation, is a promising option for unresectable or metastatic melanoma. Cutaneous side-effects have been reported including alopecia, photosensitivity, squamous cell carcinoma, keratoacanthomas, keratosis pilaris-like eruption, and palmoplantar hyperkeratosis. Acneiform eruptions have been reported in 3%-6% of the patients treated with BRAF inhibitors,and 5 cases are described in the literature. Although they responded well to topical therapies, oral antibiotics, or observation, one case required oral etretinate and the withdrawal of vemurafenib because the adverse event reached grade 3. We report one case of a severe acneiform eruption associated with vemurafenib with a good response to isotretinoin allowing continuation of the BRAF inhibitor.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results